Medpace (MEDP)

• Market cap: $10.7B
• 1 day: 0.07%
• 5 days: 3.28%
• 1 month: 2.30%
• 3 months: 5.11%
• 6 months: -15.40%
• Year to date: 12.22%
• 1 year: 9.67%
• 5 years: 308.72%
• 10 years: 1,133.97%
• Sector: Industrials
• Industry: Commercial Physical & Biological Research

About: Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Employees: 5,900

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

24% more repeat investments, than reductions

Existing positions increased: 241 | Existing positions reduced: 194

2.12% less ownership

Funds ownership: 83.15% [Q2] → 81.03% (-2.12%) [Q3]

7% less funds holding

Funds holding: 619 [Q2] → 575 (-44) [Q3]

20% less capital invested

Capital invested by funds: $10.5B [Q2] → $8.37B (-$2.1B) [Q3]

38% less first-time investments, than exits

New positions opened: 71 | Existing positions closed: 115

46% less funds holding in top 10

Funds holding in top 10: 13 [Q2] → 7 (-6) [Q3]

79% less call options, than puts

Call options by funds: $14.8M | Put options by funds: $71M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $350 2% upside
• Avg. target: $375 9% upside
• High target: $404 18% upside

5 analyst ratings

• positive: 2 40%
• neutral: 3 60%
• negative: 0 0%

Baird Eric Coldwell 32% 1-year accuracy 11 / 34 met price target	3% upside $354	Neutral Maintained	25 Nov 2024
TD Cowen Charles Rhyee 22% 1-year accuracy 2 / 9 met price target	8% upside $372	Buy Maintained	23 Oct 2024
Redburn Atlantic	18% upside $404	Buy Initiated	14 Oct 2024
Truist Securities Jailendra Singh 23% 1-year accuracy 8 / 35 met price target	16% upside $397	Hold Maintained	14 Oct 2024
UBS Dan Leonard 29% 1-year accuracy 2 / 7 met price target	2% upside $350	Neutral Downgraded	27 Sept 2024